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Abstract
Background: A subset of HIV-1 infected patients starting highly active antiretroviral treatment (HAART) experience
suboptimal CD4 response (SCR) despite virologic suppression. We studied the rate of and risk factors for SCR among
women starting HAART in the ACTG A5208 study conducted in 7 African countries. 741 HAART-naive women with
screening CD4 count <200 cells/μL were randomized to start HAART with Tenofovir/Emtricitabine plus either
Nevirapine or Lopinavir/Ritonavir.
Methods: This analysis includes the 625 women who remained on-study through 48 weeks without experiencing
protocol-defined virologic failure. We defined SCR as< 100 CD4 cells/μL increase from baseline and absolute CD4
cell count < 350 cells/μL, both at 48 weeks after HAART initiation.
Results: The baseline characteristics for the 625 women prior to HAART initiation were: median age 33 years,
screening CD4 count 134 cells/μL, and HIV-1 RNA 5.1 log10 copies/mL; 184 (29%) were WHO Stage 3 or 4.
Seventy one (11%) of these 625 women experienced SCR. Baseline factors independently associated with increased
odds of SCR included older age, lower HIV-1 RNA, positive Hepatitis B surface antigen, and site location. At 96 weeks,
only 6% of the SCR group had CD4 ≥ 350 cells/μL compared with 67% in the non SCR group.
Conclusion: After starting HAART, 11% of women with virologic suppression through 48 weeks experienced SCR.
These patients were also less likely to achieve CD4 ≥ 350 cells/μL by 96 weeks. The underlying causes and long
term clinical implications of SCR deserve further investigation.
Trial registration: Clinicaltrials.gov Identifier: NCT00089505
Keywords: HIV, Antiretroviral therapy, HAART, Immune response, CD4
Background
Highly active antiretroviral therapy (HAART) is effective
in decreasing the morbidity and mortality associated with
HIV-1 infection by reducing HIV-1 replication, which en-
ables increases in CD4 cell count and helps to restore im-
mune function [1-6]. However, in some patients with
HIV-1 infection, a substantial proportion (10-30%) of indi-
viduals show incomplete or poor CD4 cell recovery on
HAART despite suppression of HIV-1 to undetectable
levels [4].
Several studies have evaluated factors associated with
suboptimal CD4 restoration in HIV −1 infected patients
taking HAART [1-10]. Results of studies which looked
at predictors of discordant responses (with virologic sup-
pression but incomplete CD4 recovery) have been var-
ied. Furthermore, data evaluating predictors of SCR in
resource limited settings and among women are limited.
We undertook an analysis of risk factors predicting
SCR among women initiating HAART in 7 countries in
Africa who were enrolled in a randomized treatment
trial. We defined SCR (prior to analyses) as an increase
of< 100 cells/μL in CD4 count from baseline, and an ab-
solute CD4 cell count of<350 cells/μL, both at 48 weeks
after HAART initiation, among women with virologic
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SCR was selected due to a combination of a) its clinical
relevance, based on knowledge of significantly higher rates
of HIV-associated morbidity and mortality associated with
CD4<=350 cells/μL compared with >350 cells/μL, and b)
a conservative expectation (based on prior experience/lit-
erature) that the majority of patients starting ART with
CD4<200 cells/μL should experience CD4 increase of
>100 cells/μL and achieve CD4>350 cells/μL by 48 weeks
after treatment start.
Methods
This secondary analysis used data from the ACTG A5208/
OCTANE study. The design and primary results of the
OCTANE study have been previously published [11]. In
brief, study participants were 741 women with screening
CD4 count <200 cells/μL who were antiretroviral-naïve ex-
cept for prior single dose Nevirapine exposure (SD NVP)
in a subset of 241 participants. Prior Zidovudine use for up
to 10 weeks for the prevention of mother-to-child trans-
mission of HIV-1 was not exclusionary. Participants were
enrolled in 7 countries in Africa (South Africa, Botswana,
Zimbabwe, Kenya, Malawi, Zambia, and Uganda). Individ-
uals with active tuberculosis disease or severe illness re-
quiring systemic therapy or hospitalization were ineligible,
as were pregnant women. All participants were ran-
domized 1:1 to start open-label HAART with either
Lopinavir/Ritonavir plus Tenofovir/Emtricitabine (LPV/
r+TDF/FTC) or with Nevirapine plus Tenofovir/Emtri-
citabine (NVP + TDF/FTC). Participants were followed
until the last woman to enroll had completed 48 weeks
of follow-up.
CD4 cell count and HIV-1 RNA level, clinical assess-
ments, hematology and chemistry tests were evaluated at
screening, baseline (before HAART initiation) and at 4,
12, 16, and 24 weeks on study and then every 12 weeks.
Adherence was evaluated through self reported missed
dose in the past 3 days at week 4, 12, 24 and 48. The study
defined adherence by week 48 as not reporting any missed
dose at or before week 48.
Only participants who remained in follow-up on the
study through to at least 48 weeks and who did not ex-
perience protocol-defined virologic failure at or before
week 48 were included in this analysis of SCR. Virologic
failure was defined as a confirmed HIV-1 RNA decrease
of <1 log10 copies/mL from baseline at week 12, or a
confirmed HIV-1 RNA ≥400 copies/mL at or after week
24 irrespective of change in HAART regimen.
Although the screening CD4 cell count had to be 200
cells/μL or less within 90 days of enrollment there was
no restriction on the baseline CD4 cell count (obtained
from a sample drawn at the time of treatment initiation).
47 women had screening CD4 count <200 cells/μL but
enrollment CD4 count >200 cells/μL.
Statistical methods
SCR was defined as an increase of< 100 cells/μLi nC D 4
count from baseline, and an absolute CD4 cell count
of<350 cells/μL, both at 48 weeks after HAART initi-
ation, among women with virologic suppression through-
out the 48 weeks. Non-SCR was defined as..an increase
of≧100 cells/μL in CD4 count or CD4 cell count of ≥350
cells/μL.
The association between the following baseline vari-
ables and SCR within the first 48 weeks of treatment
were evaluated in both univariate tests (Wilcoxon rank
sum test for continuous variables, Fisher’s exact test for
categorical variables, and Cochran-Armitage trend test
for WHO stage) and multivariate logistic regression ana-
lysis: age, enrollment site, CD4 cell count, HIV-1 RNA,
body mass index, hepatitis B co-infection status, WHO
stage, prior exposure to SD NVP, and assigned HAART
regimen. The association between SCR in the first
48 weeks of treatment and the following post-baseline
factors was also evaluated: adherence to HAART by self
report, and the occurrence of potential HIV/AIDS-
related diagnoses within the first 48 weeks and after
48 weeks on-study. The selection of covariates in the
final multivariate models was done by stepwise selection
requiring P <0.05 for inclusion/retention of a variable,
except that screening CD4 count was forced into the
model to take account of the possibility that women
with lower screening counts might be less likely to
achieve the threshold of 350 cells/μL by week 48. A P-
value of <0.05 was considered statistically significant.
The inclusion/retention criteria for stepwise selection
refer to the threshold for forward and backward selec-
tion. This procedure selects significant variables adjusted
for other variables.
The protocol and informed consent was reviewed and ap-
proved by the following ethics committees at each site:
Medicines Control Authority of Zimbabwe, South Africa
Johannesburg - WITS - Human Research Ethics Com-
mittee: Medical (HREC), Kenya Kericho - Kenya Medical
Research Institute (KEMRI) ERC & Walter Reed Army In-
stitute of Research (WRAIR),Malawi Lilongwe – NHSRC,
South Africa Soweto - Wits HREC, Kenya Eldoret - Human
Research Protections Office (HRPO) & National Council
for Science and Technology (NCST), Zambia Lusaka - Uni-
v e r s i t yo fZ a m b i aB i o m e d i c a lResearch Ethics Committee
(UNZA BREC), Uganda Kampala – Joint Clinical Research
Center IRB; Uganda National Council for Science and
Technology, South Africa Durban - Biomedical research
Ethics committee (BREC), Botswana Human Research
Unit, and Office of Human Research Administration at
Harvard School of Public Health.
All study participants signed an informed consent be-
fore study participation. The manuscript was reviewed
and signed off by all authors.
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Six hundred and twenty five women without protocol-
defined virologic failure through 48 weeks were included in
the analysis. Baseline characteristics were: median age
33 years, median screening CD4 count 134 cells/μL, and
median HIV-1 RNA 5.1 log10 copies/mL; 184 (29%) women
were at WHO Stage 3 or 4 (Table 1). Seventy-one (11%) of
these 625 women experienced SCR, while 554 (89%) were
non SCR. Of the expected cumulative CD4 results only
2.2% were missed or not obtained during follow-up in the
study.
In univariate analysis, patients with SCR were older
than patients with non SCR (median age 37 years versus
33 years respectively, P <0.001), had lower viral load at
baseline (5.0 log10 copies/mL versus 5.2 log10 copies/mL
respectively, P =0.005), and had lower WHO stage (51%
versus 39% for stage I and 18% versus 30% for stage III/
IV, P =0.02). There was statistically significant variation
Table 1 Baseline characteristics of the 625 study participants (who did not experience protocol defined virologic
failure through to week 48), and univariate associations with suboptimal CD4 response
Characteristics All women without virologic
failure through week 48 (N= 625)
SCR (N=71) Non-SCR (N= 554) Univariate Pvalue
Age (years) Median (IQR
1) 33 (28, 38) 37 (31, 41) 32 (28, 37) <.001
Screening CD4 (cells/μL) Median (IQR) 134 (88, 168) 127 (80, 163) 135 (90, 168) 0.38
Baseline CD4 (cells/μL) Median (IQR) 132 (88, 177) 141 (104, 193) 130 (85, 174) 0.08
<50 63 (10%) 3 (4%) 60 (11%)
> =50 562 (90%) 68 (96%) 494 (89%)
HIV-1 RNA (copies/ml) Median (IQR) 5.13 (4.72, 5.53) 5.00 (4.29, 5.41) 5.15 (4.77, 5.53) 0.005
CD4/CD8 ratio Median (IQR) 0.17 (0.10, 0.25) 0.19 (0.11, 0.26) 0.17 (0.10, 0.25) 0.48
BMI (kg/m
2) Underweight:
<18.5
58 (9%) 6 (8%) 52 (9%) 0.18
Normal: 18.5-<25 372 (60%) 48 (68%) 324 (58%)
Overweight: 25- <
30
123 (20%) 14 (20%) 109 (20%)
Obese: >= 30 72 (11%) 3 (4%) 69 (12%)
Hepatitis B surface antigen Positive 35 (6%) 7 (10%) 28 (5%) 0.10
Negative 587 (94%) 64 (90%) 523 (95%)
Missing 3 0 3
WHO stage I 254 (41%) 36 (51%) 218 (39%) 0.02
II 187 (30%) 22 (31%) 165 (30%)
III/IV 184 (29%) 13 (18%) 171 (31%)
SD NVP exposure prior to study
entry
Yes 204 (33%) 17 (24%) 187 (34%) 0.11
No 421 (67%) 54 (76%) 367 (66%)
Initial randomized regimen NVP 298 (48%) 38 (54%) 260 (47%) 0.32
LPV/r 327 (52%) 33 (46%) 294 (53%)
Site Botswana 81 (13%) 8 (11%) 73 (13%) 0.001
Durban (SA
2) 44 (7%) 5 (7%) 39 (7%)
Eldoret(Kenya) 54 (9%) 16 (23%) 38 (7%)
Kericho(Kenya) 70 (11%) 6 (8%) 64 (12%)
Jo’burg
3(SA
2) 56 (9%) 2 (3%) 54 (10%)
Jo’burg
3 (Wits
4)
(SA
2)
74 (12%) 8 (11%) 66 (12%)
Malawi 50 (8%) 5 (7%) 45 (8%)
Uganda 50 (8%) 6 (8%) 44 (8%)
Zambia 55 (9%) 10 (14%) 45 (8%)
Zimbabwe 91 (15%) 5 (7%) 86 (16%)
1Inter-quartile range,
2South Africa,
3Johannesburg,
4University of Witwatersrand.
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index, exposure to single dose nevirapine, treatment
arm (nevirapine/tenofovir/emtricitabine versus lopinavir/
ritonavir/tenofovir/emtricitabine) and adherence were not
significantly associated with SCR (P>0.05). Sixty one
percent of women in the SCR group and 67% in the
non-SCR group reported missing no doses through
week 48 (adherence was not associated with SCR in uni-
variate analysis, P=0.42).
In multivariate analysis, the following variables were sig-
nificantly associated with increased odds of SCR: older
age, lower baseline HIV-1 RNA, positive hepatitis B sur-
face antigen, and enrollment site (Table 2).
At 48 weeks, 46% of women in the non-SCR group
had CD4 ≥350 cells/μL. Among the 47 women in the
SCR group followed to 96 weeks, only 6% had CD4≥
350 cells/μL, compared with 67% of the 424 women in
the non-SCR group (Figure 1).
For the 154 women who did not have week 96 CD4
results, the main reason is study completion prior to
week 96 follow-up: 140 (91%) completed the study but
were followed less than 96 weeks, 11 were lost to follow-
up prior to study completion, and 3 were due to missing
visits. Among the 625 women included in the analysis,
25 experienced virologic failure between week 48 and 96
(20 in non-SCR group and 5 in SCR group).
CD8 and CD4 response
Women with and without SCR on HAART had similar
baseline absolute CD8+ cell counts (median 790 cells/μL
vs. 702 cells/μL, respectively) and CD4/CD8 ratio (0.19
for SCR vs. 0.17 for non-SCR), although the proportion of
women with baseline CD8≥1200 cells/μL( t h eu p p e rl i m i t
of normal according to clinical laboratory reference values)
was somewhat higher in the SCR group (26% vs. 17% re-
spectively, P=0.07). The SCR group experienced a greater
decrease in absolute CD8 count prior to or at week 48
compared to the women with non SCR, CD4 response
(median change from baseline −246 vs. +27 cells/μLa t
week 48, P< 0.001). However, the CD4/CD8 ratio at week
48 was lower in the SCR group than among the non SCR’s
(median CD4/CD8: 0.31 versus 0.43 respectively, P< 0.001).
Clinical outcomes and SCR
There was no significant difference in the incidence of
new potentially HIV-1 related clinical diagnoses between
women with SCR versus without SCR both during the first
48 weeks following treatment initiation (relative risk [RR]
0.95, P=0.65) and after 48 weeks (RR 1.19, P=0.34).
Only 9 (1%) of the 625 women had disease progression
to a higher WHO Stage after week 48, with no significant
difference among those with versus without SCR (2 [3%]
vs. 7 [1%], respectively).
Discussion and conclusions
In this study among 625 highly immunocompromised
African HIV-1 infected women who achieved and main-
tained virologic suppression through 48 weeks following
initiation of first-line HAART, 11% of women experienced
SCR. This proportion is consistent with rates reported in
other studies, ranging from 10.5% to 19.0% [2-4,7], despite
varying definitions used for poor immunologic response.
While it is reassuring that the vast majority of women
demonstrated adequate CD4 recovery in this setting, it is
concerning that only 6% of patients with SCR achieved
CD4≥350 cells/μL by 96 weeks after treatment initiation.
Table 2 Multivariate analysis of risk factors for suboptimal CD4 response
Variable Odds ratio (95% CI) P-value for overall effect
Age per 10 years increase 2.32 (1.60, 3.34) <0.001
Baseline HIV-1 RNA per 1 log10 copies/mL increase 0.46 (0.30, 0.71) <0.001
Screening CD4 per 100 cells/μL) increase 0.66 (0.38,1.15) 0.14
Hepatitis B surf. antigen Positive vs. Negative 2.86 (1.05, 7.77) 0.040
Enrollment site Harare Zimbabwe
1 1 (reference site)
Botswana 2.18 (0.60, 7.89) 0.005
Durban SA
2 2.96 (0.76, 11.57)
Eldoret Kenya 9.63 (3.01, 30.82)
Kericho Kenya 2.35 (0.63, 8.77)
Johannesburg SA
2 1.15 (0.20, 6.55)
Johannesburg WITS
3 SA
2 2.97 (0.83,10.57)
Lilongwe Malawi 2.21 (0.55, 8.90)
Kampala Uganda 2.77 (0.75, 10.22)
Lusaka Zambia 5.05 (1.53, 16.67)
1Reference category
2South Africa
3University of Witwatersrand.
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clinical outcomes among women with SCR compared with
non-SCR but we had limited power to investigate the clin-
ical implications of SCR and a relatively short period of
follow-up.
Several patient factors were associated with SCR. One
of these factors was older age at HAART initiation; this
association has also been observed in other studies [1-5],
and is postulated to be related to thymus degeneration
[5]. We did not find screening CD4 count to be signifi-
cantly associated with SCR; one study showed higher
baseline CD4 related to SCR in the univariate analysis
but was not shown to be an independent risk factor [8],
while others found lower baseline CD4 to be a risk fac-
tor [9]. The finding that lower baseline HIV-1 RNA was
associated with SCR in our participants, while somewhat
counter-intuitive, has been observed in other studies
[6,10,12]. This phenomenon has been hypothesized to
result from possible prior inn ate suppression of HIV
replication, and as such a degree of CD4 gain may have
occurred already, limiting further increase [5,6]. How-
ever, baseline CD4 was similar in both the SCR and
non-SCR groups, and lower HIV-1 RNA was associated
with SCR even after controlling for screening CD4 in
multivariate analysis, suggesting that this mechanism
may not fully explain this association.
To our knowledge, the association between HBV in-
fection and SCR has not been previously observed. Some
studies have found no significant difference in the viro-
logic and immunologic responses to HAART by hepa-
titis B co-infection status [1,13]. One study found that
HIV and HBV co-infected patients had lower CD4 T cell
count at ART initiation, and HBeAg positivity status de-
creased the likelihood of achieving undetectable HIV
load after 24 weeks of ART [14]. There is need for more
studies to better understand the role of HBV on the re-
sponse to ART in HIV/HBV co infected patients.
We did not find an association between baseline body
mass index and SCR, in contrast to a recent study which
showed that 12-month CD4 lymphocyte recovery was
greatest among patients commonly classified as over-
weight (BMI range of 25–30 kg/m
2 ) [15].
Rates of SCR among women with virologic suppres-
sion differed among sites (4%-30%). The difference be-
tween sites could be related to host or virus genetic
differences, or other factors like co-infection with other
pathogens or the type of nutritional intake.
Patients with SCR are less likely to reach CD4≥ 350
cells/μL at 96 weeks, and early SCR may therefore alert
clinicians to the possibility that immune failure early on
treatment could be a predictor of long term failure.
The strengths of our study included very high rates of
follow-up and of completeness of laboratory and other
data. The study also involved a large cohort composed
entirely of women in Africa, a population severely af-
fected by the HIV-1 epidemic but in whom minimal
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Figure 1 Percentage of women with CD4≥ 350 cells/μL by time among women with SCR vs. non-SCR.
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are available. Limitations of our study included use of an
HIV-1 RNA assay with a limit of detection of 400 cop-
ies/mL (such that participants with HIV-1 RNA replica-
tion but levels <400 copies/mL were not identified); and
a sample size that was too small to detect potential clin-
ical implications of SCR. Hepatitis C (HCV) status and
intravenous drug use (IDU) data was not available and
not included in the analysis. Some studies have shown
HCV and IDU to be related to level of CD4 response
while on therapy [16,17].
Prior studies have established that lack of CD4 recon-
stitution is associated with greater risk of mortality and
morbidity [1-4,18,19]. It is therefore important to under-
stand the scope and underlying causes of the occurrence
of SCR to devise approaches to improving immune re-
constitution in these patients who are at risk of adverse
clinical outcomes even after full virologic suppression on
HAART.
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